ERBB2 and breast carcinoma: There were no significant differences in the frequency of events determining iDFS in patients stratified by molecular subtype of breast cancer with breast pCR compared to residual disease after NAC (luminal: 0.0% vs. 3.1%, p = 1.000; TNBC: 0.0% vs. 15.4%, p = 0.581; HER2+: 0.0% vs. 0.0%) (Supplementary Table S3).